
(in millions)	Healthcare		AST		Life Sciences		Total
Balance at March 31, 2024	$	2,500.9	$	1,387.6	$	182.2	$	4,070.7
Goodwill acquired	2.1		8.5		—		10.6
Measurement period adjustments to acquired goodwill	—		(0.5)		(11.6)		(12.1)
Foreign currency translation adjustments and other	6.3		19.9		0.3		26.4
Balance at March 31, 2025	$	2,509.3	$	1,415.4	$	170.9	$	4,095.7
Goodwill acquired	8.8		—		—		8.8
Measurement period adjustments to acquired goodwill	—		—		—		—
Divestiture	—		—		—		—
Foreign currency translation adjustments and other	21.0		66.8		2.6		90.4
Balance at March 31, 2026	$	2,539.0	$	1,482.3	$	173.5	$	4,194.8

See Note 3 titled, "Business Acquisitions, Divestitures, and Investments," for additional information regarding our recent business acquisitions and divestitures.

We evaluate the recoverability of recorded goodwill and indefinite-lived intangible assets annually during the third fiscal quarter, or when indicators of potential impairment exist. Our goodwill is assessed at the reporting unit level which is equivalent to the Company's reportable operating segments.

During our annual reviews for fiscal 2026, 2025, and 2024, there were no indicators that impairment of goodwill or indefinite-lived intangible assets was more likely than not.

Identifiable intangible assets are also reviewed for impairment when events and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We conduct this review on an ongoing basis, and, if impairment exists, we record the loss in the Consolidated Statements of Income during that period.

When we evaluate these assets for impairment, we make certain judgments and estimates, including interpreting current economic indicators and market valuations, evaluating our strategic plans with regards to operations, historical and anticipated performance of operations, and other factors. It is possible that unfavorable developments related to these factors in the near term could result in an impairment loss relative to intangible assets. Such an impairment loss may be material to our results of operations in the period recorded.

Information regarding our intangible assets is as follows:


(in millions)	2026				2025
March 31,	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Customer relationships	$	2,655.8	$	1,344.0	$	2,564.3	$	1,067.4
Non-compete agreements	—		—		15.1		15.0
Patents and technology	456.6		303.0		480.3		294.1
Trademarks and tradenames	235.8		106.8		247.9		105.1
Supplier relationships	54.8		29.2		54.8		26.5
Total	$	3,403.0	$	1,783.0	$	3,362.4	$	1,508.0

Certain trademarks and tradenames obtained as a result of business combinations are indefinite-lived assets. The approximate carrying value of these assets at March 31, 2026 and March 31, 2025 was $14.3 million. We evaluate our indefinite-lived intangible assets annually during the third quarter or when evidence of potential impairment exists. No impairment was recognized for fiscal years 2026, 2025 or 2024.

Total amortization expense for intangible assets was $268.2 million, $276.2 million, and $268.3 million for the years ended March 31, 2026, 2025, and 2024, respectively. Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows:


(in millions)	2027		2028		2029		2030		2031
Estimated amortization expense	$	253.1	$	248.2	$	246.3	$	241.3	$	209.1

The estimated annual amortization expense presented in the preceding table has been calculated based upon March 31, 2026 currency exchange rates.